Carmot Therapeutics (United States)

With three new drug candidates from its Carmot Therapeutics acquisition, Roche is eyeing multi-billion dollar sales potential

Roche expects half of the world's population to be overweight or obese in 10 years, per an executive for the Swiss pharma giant

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate.

Roche said its weight loss pill CT-996 helped patients lose an average of 7.3% of their weight after four weeks

Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.

The week can be summed up pretty succinctly by just saying AI and biotech.

The approval of three oral protein / peptide-based therapies has led to a substantial increase in the R&D initiatives being undertaken in this domain, to...

The first small-molecule glucagon-like peptide 1 receptor agonist to complete a phase 3 trial lowers A1c and reduces weight, the company says.

After popping earlier this week, the companies behind the drugs are on a downward swing

Roche is presenting data on its experimental weight loss drug CT-388 at this week's European Association for the Study of Diabetes (EASD) annual meeting

Two new analyses of the SELECT trial show that the GLP-1 receptor agonist improves cardiovascular health and reduces or normalizes glycemic levels irrespective of baseline A1c.

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

At 12 months, there was an average weight loss of 16.2%, with results sustained up to 24 months

Results with the GIP/GLP-1 receptor agonist were statistically superior to added insulin lispro

With IPOs still in a lull, funding flat and valuations down from their frothy highs, many have predicted an M&A boom is nigh. But Q1 saw just a modest uptick in deal-making.

Medicare coverage will catalyze market competition

The company's debut is the worst first-day showing for a U.S. listing of $1 billion or more in over two years, according to Bloomberg.

Adding tirzepatide to insulin glargine leads to greater improvements in A1c, body weight, and less hypoglycemia compared with prandial insulin lispro show data simultaneously published in JAMA.

The investigational GLP-1 agonist, taken as an oral tablet, works similarly to other drugs in the class for reducing body weight and improving glucose, without needing to be taken on an empty stomach.

Despite the slowdown in venture, the month also saw five rounds go to U.S.-based startups of a quarter-billion dollars or more—so it clearly is still possible to raise big money.